

THE EVALUATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN RENAL ELIMINATION WITH SELECTED MOLECULAR DESCRIPTORS

Jovana Trbojević¹, Jadranka Odović², Jasna Trbojević-Stanković³, Biljana Stojimirović³, Ratomir Jelić¹

¹University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Pharmacy

²Faculty of Pharmacy, University of Belgrade, Serbia

³School of Medicine, University of Belgrade, Serbia

PROCENA RENALNE ELIMINACIJE INHIBITORA ENZIMA KOJI KONVERTUJE ANGIOTENSIN SA ODABRANIM MOLEKULSKIM DESKRIPTORIMA

Jovana Trbojević¹, Jadranka Odović², Jasna Trbojević-Stanković³, Biljana Stojimirović³, Ratomir Jelić¹

¹Univerzitet u Kragujevcu, Srbija, Fakultet medicinskih nauka, Odsek za farmaciju

²Farmaceutski fakultet, Univerzitet u Beogradu, Srbija

³Medicinski fakultet, Univerzitet u Beogradu, Srbija

Received / Primljen: 07.04.2016

Accepted / Prihvaćen: 19.07.2016

ABSTRACT

Angiotensin-converting enzyme (ACE) inhibitors modulate the function of the renin-angiotensin-aldosterone system, and they are commonly prescribed antihypertensive drugs especially in patients with renal failure. In this study, the relationships between several molecular properties of eight ACE inhibitors (enalapril, quinapril, fosinopril, ramipril, benazepril, perindopril, moexipril, trandolapril) and their renal elimination data, from relevant literature, were investigated. The 'molecular descriptors of the ACE inhibitors, which included aqueous solubility data ($\log S$); an electronic descriptor, polar surface area (PSA); a constitutional parameter, molecular mass (M_r); and a geometric descriptor, volume value (Vol), as well as lipophilicity descriptors ($\log P$ values), were calculated using different software packages. Simple linear regression analysis showed the best correlation between renal elimination data and lipophilicity descriptor $AClogP$ values ($R^2 = 0.5742$). In the next stage of the study, multiple linear regression was applied to assess a higher correlation between the ACE inhibitors' renal elimination data and lipophilicity, $AClogP$, with one additional descriptor as an independent variable. Good correlations were established between renal elimination data from the literature and the $AClogP$ lipophilicity descriptor using the constitutional parameter (molecular mass ($R^2 = 0.7425$)) or the geometric descriptor (volume value ($R^2 = 0.7224$)) as an independent variable. The application of computed molecular descriptors in evaluating drug elimination is of great importance in drug research.

Keywords: Angiotensin-converting enzyme inhibitors; lipophilicity; molecular mass; elimination.

SAŽETAK

Inhibitori enzima koji konvertuje angiotenzin (ACE) modifikuju funkciju renin-angiotenzin-aldosteron sistema i predstavljaju često propisane lekova za sniženje pritiska, posebno kod pacijenata sa insuficijencijom bubrega. U ovom radu, za osam odabranih ACE inhibitora (enalapril, kvinapril, fosinopril, ramipril, benazepril, perindopril, moeksipril, trandolapril) ispitan je odnos između osobina njihovih molekula i njihove eliminacije putem bubrega. Za ispitivane inhibitore ACE korišćenjem različitih softverskih paketa izračunate su vrednosti nekoliko molekulskih deskriptora: rastvorljivost u vodi ($\log S$), elektronski deskriptor – polarna površina molekula (PSA), molekulaska masa (M_w), geometrijski deskriptor – volumen molekula (Vol) kao i deskriptor lipofilnosti ($\log P$ vrednosti). Primenom proste linearne regresione analize najbolja zavisnost dobijena je između podataka o eliminaciji inhibitora ACE putem bubrega i deskriptora lipofilnosti, $AClogP$ vrednosti ($R^2 = 0.5742$). U sledećoj fazi istraživanja primenjena je metoda višestruke regresione analize (MLR) kako bi se dobila bolja zavisnost između podataka o eliminaciji ACE inhibitora putem bubrega i njihove lipofilnosti ($AClogP$ vrednosti) uz primenu dodatnog molekulskog deskriptora kao nezavisno promenljive. Dobre korelacije su dobijene između podataka o eliminaciji putem bubrega i deskriptora lipofilnosti $AClogP$, uz primenu molekulske mase ($R^2 = 0.7425$) ili zapremine molekula ($R^2 = 0.7224$) kao nezavisno promenljive. Mogućnost primene izračunatih molekulskih deskriptora u proceni eliminacije lekova je od velikog značaja u njihovom istraživanju.

Ključne reči: Inhibitori enzima koji konvertuje angiotenzin; lipofilnost; molekulaska masa; eliminacija.



INTRODUCTION

Angiotensin-converting enzyme (ACE) inhibitors are the most commonly prescribed antihypertensive drugs today. They are a significant group of drugs widely used in the treatment of hypertension, congestive heart failure and renal failure, especially in patients with diabetes mellitus or proteinuria (1).

According to their chemical structures, ACE inhibitors can be classified into three groups: sulfhydryl-containing inhibitors (exemplified by captopril), dicarboxylate-containing (exemplified by enalapril) and phosphonate-containing inhibitors (exemplified by fosinopril). The ACE inhibitors are pro-drugs, and, following administration, they undergo ester hydrolysis into their active di-acid metabolites, with the exception of lisinopril, which is already in the di-acid form (1).

Even though they have the same usage indications, they demonstrate differences in their pharmacokinetic and pharmacodynamic properties, which may affect their clinical efficacy. The ACE inhibitors demonstrate their antihypertensive effect through their active metabolites by modulation of the renin-angiotensin-aldosterone enzymatic system and selective dilation of efferent renal arterioles. In hypertensive patients with renal failure, particularly of diabetic aetiology, ACE inhibitors are used as the drug of choice because, in addition to their antihypertensive effects, they slow the progression of microalbuminuria and proteinuria (2-5).

Some ACE inhibitors have dual routes of elimination, renal and faecal, which may be important for patients with renal failure. They can be applied in patients with end-stage renal failure who are treated with renal replacement therapy, haemo or peritoneal dialysis (1).

ACE inhibitor's pharmacological properties (absorption, protein binding, distribution, activity, duration of action and elimination) and their relationship with lipophilicity were investigated in numerous studies by chromatographic methods, spectrophotometry, capillary electrophoresis or spectrofluorimetry. ACE inhibitors were determined in pharmaceutical formulations and biological material. There are few data on the elimination of ACE inhibitors by peritoneal dialysate (6-17).

In our previous studies, we investigated the lipophilicity of several ACE inhibitors under different chromatographic conditions (18-20) and the correlation between ACE inhibitors' chromatographic or *in silico* lipophilicity data and with their protein binding (PPB) data (21) or absorption (22). In continuation of these studies, our aim was to correlate ACE inhibitors' molecular descriptors (electronic descriptor - polar surface area (PSA); constitutional parameter - molecular weight (Mw); geometric descriptor - volume value (Vol); aqueous solubility data (logS)) with their renal elimination data to determine a reliable relationship appropriate for evaluating renal elimination of the investigated group of drugs. The selection of appropriate molecular descriptors was established.

MATERIALS AND METHODS

The eight most often prescribed ACE inhibitors were investigated.

- 1. enalapril maleate**, (S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate;
- 2. quinapril hydrochloride**, [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride;
- 3. fosinopril sodium**, (4S)-4-cyclohexyl-1-[[R)-[(1S)-2-methyl-1-(1-oxopropoxy)-propoxy](4-phenylbutyl) phosphinyl]acetyl]-L-proline, sodium salt;
- 4. ramipril**, (2S,3aS,6aS)-1-[(2S)-2-[[1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl] octahydrocyclopenta[b]pyrrole-2-carboxylic acid;
- 5. benazepril hydrochloride**, (3S)-3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid hydrochloride;
- 6. perindopril erbumin**, 2-methylpropan-2-amine (2S,3aS,7aS)-1-[(2S)-2-[[2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;
- 7. moexipril**, (3S)-2-[(2S)-2-[[2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;
- 8.trandolapril**, [2S-[1[R*(R*)],2 α ,3 α ,7 α]]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid.

The software package Molinspiration Depiction Software (Molinspiration Cheminformatics) (23) was used for the calculation of the electronic descriptor polar surface area (PSA), the constitutional parameter molecular weight (Mw) and the geometric descriptor volume value (Vol) (Table 1). The ACE inhibitors' lipophilicity descriptors, different logP values (AlogP_s, AClogP, AB/logP, milogP, AlogP, MlogP, KOWWINlogP, XLOGP2, XLOGP3), and aqueous solubility data (logS), were calculated using the Virtual Computational Chemistry Laboratory software package (24).

The elimination data of the investigated compounds (Table 1) were obtained from the relevant literature (1) and using software package [DrugBank](#) (25).

Microsoft Excel 2003 and Origin 7.0 PRO (Origin Lab Corporation, USA) were used to perform the statistical analysis of the regression.

RESULTS

In this paper, the correlations between renal elimination data of selected ACE inhibitors and their calculated molecular properties were examined.



Table 1. The ACEi calculated molecular descriptors and renal elimination data collected from relevant literature (*); predicted from (A) AClogP and Vol; (B) AClogP and Mw values.

ACEi	Ren. el.*	AC logP	Vol	Mw	logS	PSA	Ren. el. ^A	Ren. el. ^B
1	100	1.52	357	376	-2.92	96	101	101
2	96	2.08	411	439	-3.81	96	77	78
3	50	3.05	539	564	-4.70	110	45	44
4	60	2.07	396	417	-3.58	96	73	72
5	88	2.09	395	424	-4.24	96	71	73
6	100	1.58	358	368	-2.63	96	97	94
7	100	1.87	462	499	-4.21	114	109	111
8	33	2.39	413	430	-3.98	96	54	53

*Ren. El. values obtained from literature (Lemke and Williams, 2013)
The numbers denote ACEi.

The five molecular descriptors (PSA, Mw, Vol, logP, logS) of the ACE inhibitors were calculated using different software packages as well as elimination data of investigated compounds from the relevant literature are shown in Table 1.

In the first stage of the investigation, correlations between the renal elimination data and calculated molecular descriptors of the ACE inhibitors were investigated using simple linear regression analysis. The renal elimination data and the 'molecular descriptors, (Vol, Mw and logS) of the ACE inhibitors showed correlations with correlation coefficients (R^2) lower than 0.2. Next, the relationship between different lipophilicity descriptors, logP values and renal elimination data were examined. The strongest correlation was found between AClogP and the renal elimination data ($R^2 = 0.5742$).

Following these results, in the next stage of the study, the relationship between renal elimination data and two different molecular descriptors of the ACE inhibitors were investigated using multiple linear regression (MLR) analysis. The AClogP was chosen as the first independent variable since it showed the best correlations with the ACE inhibitors' renal elimination data. The application of five calculated molecular descriptors (PSA, Mw, Vol, logP and logS) of ACE inhibitors was investigated by MLR analysis.

Good correlations were established between renal elimination data obtained from the literature and the AClogP lipophilicity descriptor using the constitutional parameter molecular mass ($R^2 = 0.7425$) or the geometric descriptor volume value ($R^2 = 0.7224$) as an independent variable. The values of predicted renal elimination were calculated according to the following equations:

$$\text{Renal el.}_{\text{pred 1}} (\%) = 101.1189(\pm 48.0996) - 74.9464(\pm 24.0853)\text{AClogP} + 0.3199(\pm 0.1957)\text{Vol}$$

with $n = 8$; $R^2 = 0.7224$; S.D. = 16.6729; $F = 6.5073$ Eq. 1.

$$\text{Renal el.}_{\text{pred 2}} (\%) = 102.1234(\pm 44.0093) - 73.0586(\pm 21.3470)\text{AClogP} + 0.2918(\pm 0.1614)\text{Mw}$$

with $n = 8$; $R^2 = 0.7425$; S.D. = 16.0606; $F = 7.2073$ Eq. 2.

The results obtained using MLR analysis by applying two different descriptors as independent variables are presented in Table 1 and in Fig. 1.

DISCUSSION

The clinical success of drugs depends mostly on their absorption, distribution, metabolism or route of elimination (ADME) (26). Lipophilicity is one of the most important molecular properties that influence these values, but a number of other molecular properties (such as molecular




Fig. 1. The relationship between ACEi renal elimination collected from relevant literature and (Lemke and Williams, 2013) (Series 1) and predicted in MLR using AClogP and Vol (Series 2); AClogP and Mw values (Series 3). The numbers denote ACEi.



weight (Mw), molecular volume (Vol), polar surface area (PSA) and solubility data (logS) also play important roles in drug absorption, tissue penetration, degree of distribution, degree of plasma protein binding and route of elimination (27-29).

According to the available literature, several authors investigated drugs belonging to the ACE inhibitor group, their pharmacological properties and their similarities or differences (6-10). Their acidity, lipophilicity, solubility and absorption were evaluated based on their molecular structures with the application of computer programs (27-29).

Various authors have also suggested several assays that could be employed in investigations of different drug eliminations (30-32). Most of these methods still have certain limitations, and a new approach for fast, reliable and cost-effective evaluation of the route of elimination of ACE inhibitors should be developed. The decrease in complexity and size of the average drug molecule, as well as its low logP values and high water solubility, can lead to higher probability of drugs being rapidly cleared via renal elimination (33). Since a drug's route and degree of elimination may affect a drug's duration of action and activity, the application of computed molecular descriptors in the prediction of a drug's elimination are of great importance, especially for the newly synthesized drugs.

In this study, eight ACE inhibitors—enalapril maleate, quinapril hydrochloride, fosinopril sodium, ramipril, benazepril hydrochloride, perindopril erbumin, moexipril and trandolapril—were studied to evaluate correlations between their renal elimination data obtained from the relevant literature and calculated molecular descriptors. According to the data from the literature, the degree of renal elimination of the ACE inhibitors can vary from 33% to 100% (Table 1). The lowest values of renal elimination were found for trandolapril (approximately 33%), while enalapril, perindopril and moexipril dominantly exhibit renal elimination (approximately 100%).

The correlations between the ACE inhibitors' calculated molecular descriptors and their renal elimination data obtained from relevant literature were examined. The applicability of calculated molecular descriptors in ACE inhibitor elimination evaluation was investigated. The main topic of this study was to establish an approach using simple or multiple linear regression analysis capable of predicting the renal elimination of selected ACE inhibitors based on their molecular properties.

In the first stage of the study, the relationship between all calculated logP values (ClogP, AlogPs, AClogP, AB/logP, milogP, AlogP, MlogP, KOWWINlogP, XLOGP2, XLOGP3) and renal elimination data for ACE inhibitors was investigated. Amongst all logP values, only AClogP provided a relatively good correlation ($R^2 = 0.5742$) with the renal elimination data of the ACE inhibitors.

Second, the relationship between the renal elimination data and calculated molecular descriptors of the ACE inhibitors was investigated using MLR analysis with application of two independent variables, AClogP and one of

the following: polar surface area (PSA), molecular weight (Mw), volume value (Vol) or solubility (logS) to assess their higher correlation. The best correlations were established between the ACE inhibitors' renal elimination data and the AClogP lipophilicity descriptor using the molecular weight ($R^2 = 0.7425$) or volume ($R^2 = 0.7224$) as an independent variable, indicating that these molecular properties are critical for ACE inhibitors' route of elimination. The established correlations are presented by Eq. 1 and Eq. 2. They indicate that the molecule's lipophilicity has a dominant influence on the ACE inhibitor's renal elimination, and the increase in lipophilicity led to a decrease in their renal elimination.

The correlation observed between the ACE inhibitors' renal elimination data and their *in silico* molecular descriptors (lipophilicity parameter (AClogP) and constitutional parameter (molecular mass) or geometric descriptor (volume value)) can be considered good, as proposed by Asuero et al. (34), due to the limited number of compounds. These correlations confirmed the calculation of descriptors as the technique suitable for evaluation of renal elimination of the selected compounds.

CONCLUSION

A relatively good correlation was obtained between the renal elimination data and the calculated molecular lipophilicity descriptor (AClogP) ($R^2 = 0.5742$). Furthermore, using MLR analysis with two different descriptors as independent variables and the lipophilicity descriptor (AClogP) and molecular mass or volume value as independent variables, better correlations were established (with $R^2 = 0.7425$ and $R^2 = 0.7224$, respectively). The possible application of computed molecular descriptors in evaluating drug routes of elimination can be highly useful in drug research.

The present study may be considered an effective assay and could be used as a fast, easy and cost-effective screening technique for route of elimination evaluation. The proposed methodology confirmed that lipophilicity, together with other molecular properties, is essential in a drug's route of elimination.

REFERENCES

1. Lemke TL, Williams DA (eds). The Foye's Principles of Medicinal Chemistry 6 th ed. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, 2013.
2. Giverhaug T, Falck A, Eriksen BO. Effectiveness of anti-hypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure? *J Hum Hypertens* 2004; 18: 649-54.
3. Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. *Am J HealthSystem Pharm* 2000; 57: 3-7.



4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale's Pharmacology 8 th , Elsevier, Churchill Livingstone, 2012.
5. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. *J Am Soc Nephrol* 2006; 17: 2985-2991.
6. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulphydryl angiotensin converting enzyme inhibitor. *Am J Cardiol* 1995; 75: 7F-12F.
7. Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. *Am J Hipertens* 1991; 2: 23S-28S.
8. Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. *Am J Hiperten* 1995; 8: 63S-67S.
9. Conen H, Brunner HR. Pharmacologic profile of trandolapril a new angiotensin converting enzyme inhibitor. *Am Hearth J* 1993; 125: 1525-1531.
10. Ranadive SA, Chen AX, Serajuddin TM. Relative lipophilicities and structural – pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. *Pharm Research* 1992; 9: 1480-1486.
11. Abbara Ch, Aymard G, Hinh S, Diquet B. Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection. *J Chromatogr B* 2002; 766: 199-207.
12. Gumieniczek A, Hopkala H. High performance chromatographic assay of quinapril in tablets. *Pharm Acta Helv* 1998; 73: 183-185.
13. Bouabdallah S, Trabelsi H, Bouzouita K, Sabbah S. Reversed-phase chromatography of lisinopril conformers. *J Biochem Biophys Methods* 2002; 54: 391-405.
14. El-Gindy A, Ashour A, Fattah LA, Shabana MM. Spectrophotometric and HPTLC densitometric determination of lisinopril and hydrochlorothiazide in binary mixtures. *J Pharm Biomed Anal* 2001; 25: 923-931.
15. Prieto JA, Akesolo U, Jimenez RM, Alonso RM. Capillary zone electrophoresis applied to the determination of the angiotensin-converting enzyme inhibitor cilazapril and its active metabolite in pharmaceuticals and urine. *J Chromatogr A* 2001; 916: 279-288.
16. El-Gindy A, Ashour A, Abdel Fattah L, Shabana MM. Spectrophotometric, spectrofluorimetric and LC determination of lisinopril. *J Pharm Biomed Anal* 2001; 25: 913-922.
17. Bonazzi D, Gotti R, Andrisano V, Cavrini V. Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC) *J Pharm Biomed Anal* 1997; 16: 431-438.
18. Odovic JV, Stojimirovic BB, Aleksic MB, Milojkovic-Opsenica DM, Tešić Ž.Lj. Examination of the hydrophobicity of ACE inhibitors and their active metabolites by salting-out thin-layer chromatography. *J Planar Chromat* 2005; 18: 98-103.
13. Odovic J, Stojimirovic B, Aleksic M, Milojkovic-Opsenica D, Tesic Z. Reversedphase thin-layer chromatography of some angiotensin converting enzyme (ACE) inhibitors and their active metabolites. *J Serb Chem Soc* 2006; 71(6): 621-628.
20. Odovic J, Aleksic M, Stojimirovic B, Milojkovic-Opsenica D, Tesic Z. Normal-phase thin-layer chromatography of some ACE inhibitors and their metabolites. *J Serb Chem Soc* 2009; 74(6): 677-688.
21. Odovic J, Trbojevic-Stankovic J. Correlation between Angiotensin-converting enzyme inhibitors lipophilicity and protein binding data. *Acta Medica Medianae* 2012; 51(4): 13-18.
22. Odovic JV, Markovic, BD, Injac RD, Vladimirov SM, Karljikovic-Rajic KD. Correlation between ultra-high performance liquid chromatography–tandem mass spectrometry and reversed-phase thin-layer chromatography hydrophobicity data for evaluation of angiotensin-converting enzyme inhibitors absorption. *J Chromatogr A* 2012; 1258: 94-100.
23. Molinspiration software or free molecular property calculation services. Available from URL: www.molinspiration.com
24. Tetko IV. Virtual Computational Chemistry Laboratory. Available from URL: www.vcclab.org
25. DrugBank. Available from URL: www.drugbank.ca
26. Di L, Kernsy EH. Profiling drug - like properties in discovery research. *Curr Opin Chem Biol* 2003; 7:402-408.
27. Remko M, Swart M, Matthias Bickelhaupt F. Theoretical study of structure, pKa, lipophilicity, solubility, absorption and polar surface area of some centrally acting antihypertensives. *Bioorg Med Chem* 2006; 14: 1715-1728.
14. Remko M. Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. *Chem Pap* 2007; 61(2): 133-141.
29. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherbone B, Cooper I, Platts JA. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. *J Pharm Sci* 2001; 90: 749-784.
30. Hellstern A, Hildebrand M, Humpel M, Hellenbrecht D, Saller R, Madetzki C. Minimal biliary excretion and enterohepatic recirculation of lorazepam in man as investigated by a new nasobiliary drainage technique. *Int J Clin Pharmacol Ther Toxicol* 1990; 28(6): 256–261.
31. Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. *Drug Metab Rev* 2003; 35(4): 305–317.
32. Verho M, Luck C, Stelter WJ, Rangoonwala B, Bender N. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. *Curr Med Res Opin* 1995; 13(5): 264–273 .
33. Ghose AK, Viswanadhan VN, Wendoloski JJ. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. *J Combin Chem* 1999; 1: 55–68.
34. Asuero AG, Sayago A, Gonzalez AG. The correlation coefficient: An overview. *Crit Rev Anal Chem* 2006; 36: 41-59